Article Text

Download PDFPDF
Plasma creatinine: a potential prognostic biomarker in amyotrophic lateral sclerosis?
  1. Steve Vucic
  1. Correspondence to Dr Steve Vucic, Department of Neurology, Westmead Hospital, Sydney, New South Wales 2145, Australia; s.vucic{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Plasma creatinine is a prognostic biomarker for ALS correlating with muscle strength and functional disability

There is increasing recognition of profound clinical, prognostic, neuropathological and genetic heterogeneity of amyotrophic lateral sclerosis (ALS), underscoring the need for development of reliable prognostic and outcome biomarkers that would be of vital importance in the design of cost-effective and more efficient therapeutic trials.1 The ALS functional rating scale-revised (ALSFRS-R) is a validated and reproducible biomarker of functional disability in ALS which captures clinically relevant features of disease progression, correlates with survival2 and has therefore been widely used in phase I and II trials.3 Despite the beneficial effects, the limitations of the ALSFRS-R score include its subjectivity, the non-linear …

View Full Text


  • Contributors SV is the sole contributor.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles